At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 79 enrolled
Drug / intervention
Vitamin D3drug
Likely dose
Vitamin D3 50.000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS
In Brief
A Phase 4 clinical trial evaluating Vitamin D3 for Polycystic Ovary Syndrome and Vitamin D Deficiency. Completed, enrolled 79 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the mechanism that explain the beneficial clinical effect of vitamin D treatment in women with PCOS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycystic Ovary Syndrome, Vitamin D Deficiency
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
Primary CompletionSep 2013
Study CompletionOct 2013
First PostedAug 2018
TodayJul 2026
First PostedAug 23, 2018
Enrollment StartJul 1, 2012
Primary CompletionSep 1, 2013
Study CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.9 years ago
Interventions
Vitamin D3drug
Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.